Ju Fu Tang Biotech Holdings Co., Ltd. (Ju Fu Tang Biotech) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing on 3 September 2026, covering movements up to 31 August 2026.

Authorised and Issued Share Capital • Authorised capital remained unchanged at 500.00 million ordinary shares with a par value of HKD 0.16 each, equivalent to HKD 80.00 million. • Issued shares were steady at 301.86 million, with no treasury shares recorded. No new shares were issued or cancelled during the month.

Public Float Status • The company confirmed full compliance with the Hong Kong Stock Exchange’s minimum public float requirement of 25% of the issued share class as at 31 August 2026.

Share Option Scheme Activity • One active scheme adopted on 24 March 2016 continues to hold 9.14 million options outstanding. • Exercise price: HKD 0.163 per share; grant date: 18 March 2022; expiry: 17 March 2027. • No options were exercised, lapsed, or cancelled in August, leaving the potential dilution unchanged.

Other Equity Instruments • The issuer reported no warrants, convertibles, additional option arrangements, or other equity-linked instruments outstanding or issued during the period.

Overall, Ju Fu Tang Biotech’s equity structure and share capital base remained static through August 2026, with confirmed adherence to listing rules on public float and no capital-raising activities undertaken during the month.